[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Laboratory Sciences
November 2006

Regulation of Corneal Repair by Particle-Mediated Gene Transfer of Opioid Growth Factor Receptor Complementary DNA

Author Affiliations

Author Affiliations: Departments of Neural & Behavioral Sciences (Drs Zagon, Malefyt, and McLaughlin), and Ophthalmology (Dr Sassani), The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey.

Arch Ophthalmol. 2006;124(11):1620-1624. doi:10.1001/archopht.124.11.1620

Objective  To determine whether molecular manipulation of the opioid growth factor receptor (OGFr) alters corneal reepithelialization following central corneal abrasion in rats.

Methods  The plasmid pcDNA3.1 + OGFr, carrying the rat OGFr complementary DNA in both the sense and antisense orientations, and empty vector (EV), were delivered by gene gun to the rat cornea. After 24 hours, corneas were abraded and reepithelialization was documented by fluorescein photography. Twenty-four hours after wounding, DNA synthesis (with bromodeoxyuridine) was examined.

Results  Eyes transfected with sense constructs of OGFr had corneal defects that were 24%, 52%, and 50% larger than the EV group at 16, 24, and 28 hours, respectively. Conversely, corneas transfected with antisense constructs of OGFr had corneal defects that were 56% and 48% smaller than the EV group at 16 and 24 hours, respectively. Bromodeoxyuridine labeling in the basal and suprabasal layers of the antisense group were increased 3.3- and 3.7-fold, respectively, in DNA synthesis from corresponding EV layers; DNA synthesis was comparable in the sense and EV groups.

Conclusions  Excess OGFr delays reepithelialization, whereas attenuation of OGFr accelerates repair of the corneal surface.

Clinical Relevance  Inhibition of opioid growth factor action using gene therapy could be important in the treatment of corneal diseases such as nonhealing and recurrent erosions, diabetic keratopathy, and neurotrophic keratitis.